GUSTO II trial.
The GUSTO II trial will investigate the role of antithrombin therapy in acute coronary syndromes, comparing standard doses of heparin with the specific antithrombin agent recombinant hirudin. The two drugs will be compared as primary therapy in patients with unstable angina or patients with myocardial infarction (MI) unsuitable for thrombolysis, and as post thrombolysis treatment in patients who fulfil standard criteria for thrombolysis therapy. A total of 12,000 patients will be studied in a global, multifactorial trial.
Aylward
P
P
Flinders Medical Centre, Adelaide, SA.
D000789:Angina, Unstable / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy
D011994:Recombinant Proteins; D006493:Heparin